Here's Why QuidelOrtho (QDEL) is a Strong Growth Stock

QuidelOrtho (QDEL), an in-vitro diagnostics provider, is highlighted as a compelling growth stock, holding a Zacks #2 (Buy) Rank and an 'A' Growth Style Score. The company projects 29.2% year-over-year earnings growth for the current fiscal year, supported by recent analyst upgrades to its fiscal 2025 earnings estimate to $2.39 per share, and a historical average earnings surprise of +70.8%. These robust metrics position QDEL as a strong consideration for growth-oriented portfolios.

Analysis

QuidelOrtho (QDEL), an in-vitro diagnostics provider, presents a compelling growth profile according to the Zacks rating framework. The company holds a #2 (Buy) rank, complemented by top-tier 'A' scores for both its overall VGM (Value, Growth, Momentum) and specific Growth style. This rating is underpinned by a significant forecast for 29.2% year-over-year earnings growth in the current fiscal year. Reinforcing this positive outlook, the Zacks Consensus Estimate for fiscal 2025 has increased to $2.39 per share following upward revisions by two analysts within the last 60 days. Furthermore, QDEL has a notable history of outperformance, demonstrating an average earnings surprise of +70.8%, which suggests a pattern of exceeding market expectations. The combination of strong forward projections, improving analyst sentiment, and a track record of earnings beats forms the basis for its classification as a strong growth stock.

Key Decisions for Investors

• Given the strong quantitative signals, including a 29.2% earnings growth forecast and positive analyst revisions, growth-focused investors should consider QDEL a candidate for their watch list or portfolio.
• Investors should monitor upcoming earnings announcements to validate if the company can maintain its significant historical earnings surprise of +70.8%, as this is a key driver of the current bullish thesis.
• While the Zacks #2 (Buy) rank and 'A' Growth Score are positive indicators, it is crucial to note these are based on a specific proprietary model and should be used in conjunction with broader fundamental analysis of the in-vitro diagnostics market.